Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

New Sopheon Software Release

7 Apr 2022 07:00

RNS Number : 5540H
Sopheon PLC
07 April 2022
 

SOPHEON PLC

("Sopheon" or the "Company")

 

Sopheon Boosts Innovation System with Real-time Information and Collaboration Enhancements

Sopheon, the leading international provider of software and services for Enterprise Innovation Management solutions, today announced a series of upgrades to its flagship product, Accolade®.

 

With an unprecedented level of transparency resulting in better analysis, a higher level of risk identification and improved reporting, Accolade enables stakeholders to make faster, fact-based decisions that drive innovation forward.

Accolade is a flexible and scalable single innovation system that provides the ability to control and manage innovation and new product development programs more effectively. Hundreds of long-standing blue-chip customers have experienced superior strategy-to-execution performance, increased time to market, streamlined operational costs and greater product success.

 

"Innovation projects face many speed bumps on the road from inception to the market. Sopheon has smoothed the road to innovation success with these latest communication and collaboration enhancements," said Michael Bauer, chief product officer of Sopheon. "Accolade provides a secure, self-service environment that allows stakeholders to be self-reliant in tracking processes and progress. By staying informed on a real-time basis, without needing the involvement of project managers, key stakeholders are empowered to make faster, fact-based decisions. Sopheon's Accolade provides the perfect mix of self-reliance, accountability, transparency and decision-making capabilities for ensuring new product success."

 

Benefits of the latest Accolade enhancements include:

 

Real-time information sharing - Accolade provides an easy and secure way for project and portfolio managers to set up and share information. Stakeholders can see live data automatically on-demand without needing a license for Accolade. This provides visibility into product portfolio performance and ensures that stakeholders are completely informed and aligned with relevant information that is always up to date.

 

Deeper collaboration - The addition of Slack to Sopheon's support for Microsoft Teams extends Accolade's communication and collaboration capabilities. The improved and fully integrated experience enables users to easily engage team members where they are most comfortable working in Accolade.

 

Valuable new insights - Sopheon's Trended Metrics is a powerful evaluation tool that helps users determine whether their product or portfolio is on track. Accolade automatically highlights and shows how specific metrics are trending and gives users an immediate indication where problems are likely to occur. It also captures updates since previous communications with stakeholders.

 

For further information contact:

Andy Michuda (Executive Chairman)Arif Karimjee (CFO)

Sopheon plc

+ 44 (0) 1276 919 560

Carl Holmes/Edward Whiley (Corporate Finance)

Alice Lane (ECM)

finnCap

+ 44 (0) 20 7220 0500

 

Sopheon and Accolade are trademarks of Sopheon plc. All other trademarks are the property of their respective owners.

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete enterprise innovation management solutions including software, expertise, and best practices, that enable them to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange. For more information, please visit www.sopheon.com.  

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEAELKEDSAEAA
Date   Source Headline
30th Jan 201810:27 amRNSIssue of Equity
29th Jan 20187:00 amRNSTrading Update
4th Jan 20182:05 pmRNSSecond Price Monitoring Extn
4th Jan 20182:00 pmRNSPrice Monitoring Extension
4th Jan 20187:00 amRNSTrading Update
22nd Dec 20171:01 pmRNSHolding(s) in Company
22nd Dec 201712:37 pmRNSConversion of Loan Stock
8th Dec 20177:00 amRNSAmendment to the Terms of Convertible Loan Stock
9th Nov 20177:00 amRNSCertis Europe Partners with Sopheon
19th Oct 20177:00 amRNSSopheon Funding Award
11th Oct 201710:44 amRNSDirector/PDMR Shareholding
2nd Oct 20177:00 amRNSIssue of Equity
26th Sep 20177:00 amRNSSopheon "Leader" in Strategic Portfolio Management
5th Sep 20177:00 amRNSSopheon's Accolade Software beyond innovation
24th Aug 20177:00 amRNSHalf Yearly Report
21st Jul 201710:32 amRNSDirector Shareholdings
6th Jul 20177:00 amRNSAccolade Release 11.2
29th Jun 20177:00 amRNSNew Approach to Product Development with Accolade
13th Jun 201712:04 pmRNSDirector Shareholdings
8th Jun 201712:09 pmRNSResult of AGM
8th Jun 20177:00 amRNSAGM Statement
26th May 20174:33 pmRNSIssue of Equity
26th Apr 20173:50 pmRNSIssue of Equity
12th Apr 201712:01 pmRNSIssue of Equity
7th Apr 20171:37 pmRNSDirector Shareholdings
31st Mar 20177:00 amRNSDirector Shareholdings
31st Mar 20177:00 amRNSIssue of Equity
23rd Mar 20177:00 amRNSFinal Results
23rd Feb 20177:00 amRNSAccolade Release 11.1
16th Feb 20177:00 amRNSGrant of Options / PDMR dealing
30th Jan 20177:00 amRNSTrading Update
21st Nov 201611:50 amRNSIssue of Equity
3rd Nov 20168:00 amRNSAccolade Release 11.0
29th Sep 201612:41 pmRNSIssue of Equity
22nd Sep 20169:09 amRNSIssue of Equity
15th Sep 20163:09 pmRNSIssue of Equity
25th Aug 20167:00 amRNSHalf Yearly Report
28th Jul 20165:01 pmRNSHolding(s) in Company
26th Jul 201610:49 amRNSHolding(s) in Company
12th Jul 201610:48 amRNSHolding(s) in Company
29th Jun 20165:32 pmRNSDirector Dealing
16th Jun 20164:22 pmRNSDirector Dealing
14th Jun 20164:18 pmRNSDirector Dealing
10th Jun 20162:13 pmRNSDirector Dealing
9th Jun 201611:37 amRNSResult of AGM
9th Jun 20167:00 amRNSAGM Statement
31st May 20163:09 pmRNSIssue of Equity
5th May 20161:25 pmRNSHolding(s) in Company
4th May 20167:00 amRNSAccolade Release 10.3
3rd May 20161:27 pmRNSDirector Shareholdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.